Managed Healthcare Executive13d
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
Man, 39, Given 12 Months to Live After Cancer Diagnosis — Which Was Discovered as He Struggled to Eat a Sandwich
A man discovered that he has stage four cancer, and an estimated 12 months to live, all because he struggled to eat a ...
Targeted Oncology5d
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.
MPR11d
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...